Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.

Approximately 15% of locally advanced colorectal cancers (CRC) have DNA mismatch repair deficiency (dMMR), resulting in high microsatellite instability and a high tumour mutational burden. These cancers are frequently sensitive to therapy with immune-checkpoint inhibitors (ICIs) in the metastatic setting. This sensitivity seems to be even more pronounced in locally advanced disease, and organ preservation has become a realistic aim in ongoing clinical trials involving patients with dMMR rectal cancer. By contrast, metastatic CRCs with proficient DNA mismatch repair (pMMR) are generally resistant to ICIs, although a proportion of locally advanced pMMR tumours seem to have a high degree of sensitivity to ICIs. In this Review, we describe the current and emerging clinical evidence supporting the use of neoadjuvant ICIs in patients with dMMR and pMMR CRC, and the potential advantages (based on a biological rationale) of such an approach. We discuss how neoadjuvant 'window-of-opportunity' trials are being leveraged to progress biomarker discovery and we provide an overview of potential predictive biomarkers of response to ICIs, exploring the challenges faced when evaluating such biomarkers in biopsy-derived samples. Lastly, we describe how these discoveries might be used to drive a rational approach to trialling novel immunotherapeutic strategies in patients with pMMR CRC, with the ultimate aim of disease eradication and the generation of long-term immunosurveillance.
Competing Interests: Competing interests C.J.M.W. has received institutional research funding from GSK, Merck Serono, and Roche Diagnostics and honoraria from Merck Serono, Roche Diagnostics, Servier and Tactics MD. A.M.P. has received institutional research funding from GSK. P.M.K. has received institutional research funding from Agenus. J.F.S. has received institutional research funding from Amgen, GSK, Merck Serono, and Pierre Fabre Medicament and honoraria from AstraZeneca, Biocartis, BMS, GSK, Jazz Pharmaceuticals, Merck Serono, Pierre Fabre Medicament, Roche Diagnostics, Sanofi, Seagen, Servier and Takeda. C.S.R. has received institutional research funding from GSK. G.W.M. has received institutional research funding from AstraZeneca. S.T. has received institutional research funding from GSK.
(© 2024. Springer Nature Limited.)